Dianthus Therapeutics targets severe autoimmune diseases with DNTH103. Read more on DNTH's promise amid competitive ...

The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised ...

In a statement, Argenx said that the subcutaneously administered drug is the first “meaningful” new treatment option for the approximately 24,000 people living with CIDP in the US in more than ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

At the moment, drug treatment for CIDP relies on corticosteroids or high-dose intravenous immune globulins, such as Takeda’s Hyqvia and Gammagard Liquid, or a procedure called plasmapheresis ...

incorporating branch points to accommodate individual patient needs and treatment responses. Criteria for “typical CIDP” emphasize the occurrence of proximal and distal numbness and weakness with ...

Read more about the treatment of CIDP The patient was an 84-year-old male who was on maintenance therapy with IVIG infusions twice a week for the last 10 years. He had a history of hypertension.

Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic ...

March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of ...